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a b s t r a c t
Streptococcus pneumoniae (S. pneumoniae) is a bacterium commonly found in the throat of
young children. Pneumococcal serotypes can cause a variety of invasive and non-invasive
diseases such as meningitis and pneumonia. In 2000 a vaccine was introduced in the USA
that not only prevents vaccine type disease but has also been shown to eliminate carriage of
the vaccine serotypes. One key problem with the vaccine is that it has been observed that
the same sequence types (genetic material found in the serotypes) are able to manifest
in more than one serotype. This is a potential problem if sequence types associated with
invasive disease may express themselves in multiple serotypes.
We present a basic differential equation mathematical model for exploring the
relationship between sequence types and serotypes where a sequence type is able to
manifest itself in one vaccine serotype and one non-vaccine serotype. An expression for
the effective reproduction number is found and an equilibrium and then a global stability
analysis carried out. We illustrate our analytical results by using simulations with realistic
parameter values.
© 2010 Elsevier B.V. All rights reserved.
1. Introduction
Streptococcus pneumoniae, or pneumococcus, is a bacterium which was discovered simultaneously and independently
in the late nineteenth century by the American physician George Miller Sternberg and the French chemist Louis Pasteur.
Since then approximately 90 serotypes have been identified, although themajority of pneumococcal infection and disease is
associatedwith amuch smaller number. The serotype is the polysaccharide capsule that surrounds pneumococcal sequence
types. There are hundreds of known pneumococcal sequence types. Pneumococcal serotypes and sequence types have been
observed to be highly correlated, with the most invasive sequence types corresponding to the most invasive serotypes.
Pneumococcus is commonly carried in the nasopharynx (the area of the upper throat that lies behind the nose) of children
less than two years of age, predominantly causing no infection. However, pneumococcus can cause various infections such
as otitis media (an ear infection, common in infants), sinusitis and pneumonia, and invasive diseases such as meningitis
and septicaemia. It may be passed from person to person through direct contact and respiratory droplets (e.g. coughs and
sneezes) of an infected person.
In the past antibiotics were primarily used to treat pneumococcal infections and disease. However this led to an
increase in the number of antibiotic-resistant pneumococcal strains. Therefore, in an effort to prevent the development
of pneumococcal infection and disease, vaccines have been developed. The two vaccines currently in use in the UK are
the 23-valent polysaccharide vaccine and the 7-valent conjugate vaccine. The 23-valent polysaccharide vaccine contains
purified capsular polysaccharide from 23 different pneumococcal serotypes whilst the 7-valent conjugate vaccine consists
of purified capsular polysaccharide from 7 different pneumococcal serotypes conjugated to protein.
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The 23-valent polysaccharide vaccine was introduced in the UK in 2003 and is recommended for adults aged 65 years
and over and anyone over the age of five years who is at increased risk of developing pneumococcal infection (e.g. those
who are immunocompromised). This vaccine is not effective in children under two years old as their immune systems are
not sufficiently well developed.
However more recently the 7-valent conjugate vaccine has been developed. This vaccine is effective in preventing pneu-
mococcal infection for those under two years old. This vaccine was introduced to the immunisation schedule of children
under two years old in the UK in September 2006.
The 23-valent polysaccharide vaccine is 60%–70% effective against preventing invasive disease from the 23 vaccine
serotypes which account for approximately 85%–90% of the circulating pneumococcal strains. On the other hand, the
conjugate vaccine is effective against preventing invasive disease from much fewer serotypes, but it has been shown to
have almost 100% efficacy in preventing vaccine type invasive disease. One of the other advantages of the conjugate vaccine
is that it has been shown to prevent carriage of these serotypes, allowing for the possibility of herd immunity. This occurs
when immunising selected individuals in a community protects thewhole community. It is thought that, since the conjugate
vaccine reduces the carriage of the seven vaccine serotypes in children less than two years old, the overall carriage of these
serotypes will reduce. Children under two years old are the primary carriers of pneumococcus. Therefore, it is believed that
vaccination of this group may prevent the transmission to adults.
However, there are potential problems associated with the use of these vaccines that may prevent them from having
long-term efficacy.
Firstly since these vaccines act only on a limited number of the possible 90 pneumococcal serotypes; there is the potential
for serotype replacement where the carriage of non-vaccine serotypes becomes more prevalent, replacing the vaccine
serotypes, possibly causing non-vaccine type infection and disease.
The second problem is that it has been observed that the same sequence types are able to manifest themselves in more
than one serotype. This is a problem if sequence types associated with invasive disease are able to manifest themselves in
non-vaccine type serotypes. We are interested in investigating this.
To emphasise the potential problem we consider data presented in [1]. This shows sequence types with multiple
serotypes found in a Scottish study of invasive pneumococcal isolates carried out between January and June 2003. Of most
interest in this studywas serotype 14whichwas reported as having increased invasive disease potential andwas discovered
to be associated with ten different sequence types. The data show that six of the sequence types associated with serotype 14
are able to manifest themselves in multiple serotypes. Five of these serotypes are not included in the conjugate vaccine.
Therefore there is the potential for pneumococcal infection or disease of these non-vaccine serotypes to become more
prevalent.
In this study it was also noted that the non-vaccine serotype 8 was the second most common serotype causing invasive
disease in Scotland. From the data it can be seen that sequence type 9, the major sequence type of serotype 14, also exists as
serotype 8. Therefore, there is the potential for invasive disease of serotype 8 to increase, and not be covered by the vaccine,
if all of the sequence type 9 pneumococcal capsules switched to serotype 8.
We are interested in developing simple mathematical models to consider the problem of sequence types being able to
manifest themselves inmore than one serotype. This ismotivated by thework in [2]. Lipsitch considers two serotypemodels
in which he investigates the competition between a vaccine type serotype and a non-vaccine type serotype. However he
does not consider sequence types in hismodel. Therefore tomodelwhat happenswhen sequence typesmanifest themselves
in more than one serotype, a simplified version of Lipsitch’s model was altered and classified in terms of sequence type. In
Lipsitch’s paper the possibility of individuals being simultaneously co-infected with two serotypes was considered. In this
paper due to space restrictionswe consider a simplemathematicalmodel for the transmissiondynamics of the diseasewhere
there is one sequence type associated with two serotypes. In future papers we hope to build on this work by considering
multiple sequence types and individuals being able to be simultaneously co-infected with multiple serotypes.
In the following section we shall describe the basic mathematical model which we shall use to describe the spread of
the pneumococcus. This is followed by an equilibrium analysis. Next we derive the effective reproduction number for this
model. This is followed by a global stability analysis. Some simulations and a brief summary conclude the paper.
2. Mathematical model
The model consists of one sequence type associated with two serotypes. This model includes four possible classes of
hosts:
those unvaccinated susceptible to carriage of sequence type 1, (X);
those unvaccinated carrying sequence type 1, (T1);
those vaccinated susceptible to carriage of sequence type 1, (V );
and
those vaccinated carrying sequence type 1, (VT1).
A proportion f of children receive the vaccine. The sequence type T1 can express itself as either serotype 1 (Y1) or serotype
2 (Y2) with proportions pT1 or (1 − p)T1 respectively. The vaccine is wholly effective against serotype 1 but completely
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Fig. 1. Flow diagram for model equations.
ineffective against serotype 2. Thus the vaccine will not necessarily eliminate carriage of the sequence type as it can express
itself as both serotypes. If a vaccinated host is carrying sequence type 1 it must be expressed as serotype 2.
Following [2] we assume that susceptible children enter the population of interest at a constant rate L and that children
leave the population at per capita rate u. We are thinking of the population being studied as young children as this is
one of the populations where the effects of pneumococcal carriage can be important (the other being the elderly). We
assume that transmission is determined by the sequence type not the serotype and assume amass action transmission term
with coefficient β1. Thus unvaccinated and vaccinated susceptibles are infected at rates β1X(T1 + VT1) and β1V (T1 + VT1)
respectively. Either vaccinated or unvaccinated childrenwho are carrying the sequence typemay become susceptible again,
independently, at per capita rate γ .
The differential equations which describe the progress of the disease are as follows (Fig. 1):
dX
dt
= L(1− f )− uX − β1X(T1 + VT1)+ γ T1,
dT1
dt
= β1X(T1 + VT1)− (γ + u)T1,
dV
dt
= Lf − uV − β1V (T1 + VT1)+ γ VT1 ,
and
dVT1
dt
= β1V (T1 + VT1)− (γ + u)VT1 .
(1)
3. Equilibrium solutions
We look for equilibrium solutions Xˆ, Tˆ1, Vˆ and VˆT1 to the differential equations (1). Adding the equilibrium versions of
(1)(i) and (ii) we deduce that Xˆ+Tˆ1 = (1−f ) Lu and from (1)(iii) and (1)(iv) Vˆ+VˆT1 = f Lu . Next substituting Xˆ = (1−f ) Lu−Tˆ1
into (1)(ii) and Vˆ = f Lu − VˆT1 into (iv) and adding gives
β1

L
u
− (Tˆ1 + VˆT1)

(Tˆ1 + VˆT1) = (γ + u)(Tˆ1 + VˆT1).
Thus Tˆ1 + VˆT1 = 0 or Tˆ1 + VˆT1 = Lu − γ+uβ1 .
(i) If Tˆ1 + VˆT1 = 0 then Tˆ1 = VˆT1 = 0 as all feasible equilibrium solutions are positive. Hence Xˆ = (1− f ) Lu and Vˆ = f Lu and
we have the carriage-free equilibrium (CFE)
(1− f ) L
u
, 0, f
L
u
, 0

. (2)
(ii) If Tˆ1 + VˆT1 = Lu − γ+uβ1 , dividing the equilibrium equations (1)(ii) and (iv) we deduce that
Tˆ1
VˆT1
= Xˆ
Vˆ
= (1− f )
L
u − Tˆ1
f Lu − VˆT1
.
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Thus (1 − f )VˆT1 = f Tˆ1. Hence Tˆ1 = (1 − f )k and VˆT1 = fk for some k. But k = Tˆ1 + VˆT1 = Lu − γ+uβ1 . It follows that
Tˆ1 = (1− f )

L
u − γ+uβ1

, Xˆ = (1− f ) γ+u
β1
, VˆT1 = f

L
u − γ+uβ1

and Vˆ = f γ+u
β1
. Hence the equilibrium solution is
(1− f )γ + u
β1
, (1− f )

L
u
− γ + u
β1

, f
γ + u
β1
, f

L
u
− γ + u
β1

. (3)
For this equilibrium to be feasible we must have β1Lu(γ+u) ≥ 1. We define
R = β1L
u(γ + u) . (4)
Hence if R ≤ 1 there is only the CFE (2) whereas for R > 1 there is the CFE and a unique carriage equilibrium (CE) given
by (3).
At the CE, Yˆ1 = pTˆ1 = p(1− f )

L
u
− γ + u
β1

,
and Yˆ2 = (1− p)Tˆ1 + VˆT2 = (1− p(1− f ))

L
u
− γ + u
β1

,
are the number of children carrying serotype 1 and serotype 2 respectively.
4. The effective reproduction number
The effective reproduction number is defined as the expected number of secondary cases caused by a ‘typical’ infected
individual entering a completely susceptible population at equilibrium [3]. It is called the effective reproduction number
rather than the basic reproduction number because vaccination has been included in the model. There are two types of
infected individuals, unvaccinated (type 1) and vaccinated (type 2). Hencewe consider the next generationmatrixM = (mij),
wheremij is the expected number of type i infected individuals caused by a single type j infected individual entering the CFE
during his or her entire infectious lifetime. The average infectious lifetime of an individual of either type is 1
γ+u . It is then
easy to show that
M =

β1L(1− f )
u(γ + u)
β1L(1− f )
u(γ + u)
β1Lf
u(γ + u)
β1Lf
u(γ + u)
 .
Re is the spectral radius, or largest absolute value of the eigenvalues of this matrix [3]. It is straightforward to see that
Re = R = β1Lu(γ + u) . (5)
Re is independent of the vaccination fraction, f . This is because vaccinated individuals can still carry the sequence type
although they must express it as serotype 2. We also note that for Re > 1 the CE can be written as
(1− f )
Re
Nˆ, (1− f )Nˆ

1− 1
Re

,
f
Re
Nˆ, f Nˆ

1− 1
Re

where Nˆ = Lu is the equilibrium population size.
5. Global stability analysis
Adding Eqs. (1) we deduce that if N = X + T1 + V + VT1 is the total population size,
dN
dt
= L− uN.
So N → Lu as t →∞. From (1) we deduce that
d
dt
(X + V ) = L− u(X + V )− β1(X + V )(T1 + VT1)+ γ (T1 + VT1), (6)
and
d
dt
(T1 + VT1) = β1(X + V )(T1 + VT1)− (γ + u)(T1 + VT1). (7)
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If (T1+VT1)(0) = 0 then (T1+VT1)(t) = 0 for all t so it is straightforward to see that X → (1− f ) Lu and V → f Lu as t →∞.
If (T1 + VT1)(0) > 0 it is easy to show that (T1 + VT1)(t) > 0 ∀t .
We shall consider two cases: (i) Re < 1 and (ii) Re ≥ 1.
(i) Re < 1.
Choose ϵ > 0 such that−k0 = (γ + u)(Re − 1)+ β1ϵ < 0. ∃ t0 such that for t ≥ t0, X + V ≤ Lu + ϵ. Therefore for t ≥ t0
from (7)
1
T1 + VT1
d
dt
(T1 + VT1) ≤ β1

L
u
+ ϵ

− (γ + u) = −k0 < 0.
Hence T1 + VT1 → 0 as t →∞. Therefore T1 → 0, VT1 → 0 and X + V = N − (T1 + VT1)→ Lu as t →∞. Now from (1)(i)
dX
dt
→ L(1− f )− uX, as t →∞.
Hence given ϵ > 0, ∃ t1 such that for t ≥ t1,
dX
dt
< L(1− f )− uX + ϵ.
Therefore by standard comparison theorems [4] we conclude that for t ≥ t1, X is bounded above by X0(t) where X0(t) is
the solution to
dX0
dt
= L(1− f )− uX0 + ϵ,
and X0(t1) = X(t1).
It is straightforward to show that X0(t) → (1−f )L+ϵu as t → ∞. Hence lim supt→∞ X(t) ≤ (1−f )L+ϵu . A similar argument
shows that lim inft→∞ X(t) ≥ (1−f )L−ϵu . But ϵ is arbitrary and lim supt→∞ X(t) ≥ lim inft→∞ X(t). So X → (1−f )Lu and
V = (X + V )− X → f Lu as t →∞, i.e., the CFE is globally asymptotically stable (GAS).
(ii) Re ≥ 1.
Given ϵ > 0 ∃ t2 such that for t ≥ t2, Lu − ϵ ≤ N ≤ Lu + ϵ. Hence
d
dt
(T1 + VT1) = [β1(N − (T1 + VT1))− (γ + u)](T1 + VT1),
≤
[
β1

L
u
+ ϵ

− β1(T1 + VT1)− (γ + u)
]
(T1 + VT1),
= (γ + u)(Re − 1)+ ϵβ1 − β1(T1 + VT1) (T1 + VT1).
Using the same comparison technique as in Case (i) we deduce that T1 + VT1 → (γ+u)(Re−1)β1 and therefore X + V =
N − T1 − VT1 → Lu − (γ+u)(Re−1)β1 =
γ+u
β1
as t →∞. Now consider
d
dt
(X + T1) = L(1− f )− u(X + T1).
We deduce that X + T1 → (1− f ) Lu as t →∞. So (V + VT1) = N − (X + T1)→ f Lu as t →∞.
Let X = (1− f )X, T1 = (1− f )T 1, V = f V and VT1 = f V T1 . X + T 1 and V + V T1 → Lu as t →∞.
dT 1
dt
= β1X(T1 + VT1)− (γ + u)T 1,
→ β1

L
u
− T 1

L
u
− γ + u
β1

− (γ + u)T 1, as t →∞,
= β1L
u

L
u
− γ + u
β1

− β1L
u
T 1.
A comparison argument similar to those used above then implies that
T 1 → Lu −
γ + u
β1
, as t →∞.
Hence T1 = (1− f )T 1 → (1− f )

L
u
− γ + u
β1

,
X = (X + T1)− T1 → (1− f ) γ + u
β1
,
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Fig. 2. Typical simulation with Re > 1.
V = (X + V )− X → f γ + u
β1
,
and VT1 = (T1 + VT1)− T1 → f

L
u
− γ + u
β1

, as t →∞.
So we have shown that provided that (T1 + VT1)(0) > 0, if Re = 1 the system approaches the CFE and if Re > 1 the system
approaches the CE as t →∞.
We have thus proved the following theorem:
Theorem 1. (i) For Re ≤ 1 system (1) has only the CFE given by (2) which is GAS as time becomes large.
(ii) For Re > 1 there are two equilibria, the CFE and a unique CE given by (3). If there is no disease initially present the system
tends to the CFE. If there is any disease initially present the system goes to the CE as time becomes large.
6. Simulations
We aim to illustrate our results with simulations using realistic parameter values although the simulations are intended
for illustrative purposes rather than to model any particular situation in detail. If we think of the population of children
under two years old in Scotland, that is an appropriate population to consider as pneumococcal carriage and transmission
is an important issue here. An extremely crude estimate of the size of this population is Nˆ = 150 000 children. We assume
that this population is at equilibrium (it is quite close to this and we are merely giving illustrative parameter values). We
take the unit of time to be one week. This gives u = 1104/wk = 9.615× 10−3/wk and L = uNˆ = 1442.31/wk.
Weir [5] performs a systematic review of the average duration of pneumococcal carriage in children under two years old
using data from Sweden and the USA and finds 1
γ
= 7.1 wk on average so we take γ = 0.1408/wk. Re for S. pneumoniae has
been estimated in [6] as roughly 1.49. Another study in [7] gives Re to be 1.8–2.2. We take Re = 1.5, which using (5) gives
β1 = 1.5041 × 10−6/wk. Note that in practice both β1 and γ will depend on the particular serotype under consideration.
We take f = 0.6 for illustrative purposes. These parameters give a CFE of (60000, 0, 90 000, 0) and a CE of (40000, 20000,
60000, 30000).
Simulations were performed with a wide variety of initial conditions and some other parameter values and in each case
for Re > 1 and disease initially present the system tended to the unique CE confirming our analytical results. The simulations
were carried out using the numerical integration package SOLVER. Fig. 2 shows one such simulation with initial values
X(0) = 149 000, T1(0) = 1000, V (0) = 0 and VT1(0) = 0.
Simulations were also performed for other parameter values with Re ≤ 1 and in each case the disease died out whatever
the starting values, again confirming our mathematical conclusions.
7. Summary and conclusions
We have discussed a basic mathematical model for the transmission of pneumococcal disease. The model assumed only
one sequence typewhich could express itself as two serotypes. Simplemodels such as this provide a building block onwhich
more complex and realistic mathematical models can be based. We intend to examine the effect of multiple sequence types
and co-infection in future work. Our work has been motivated by the mathematical models in [2].
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We derived the differential equations which described the progress of the disease and deduced an expression for the
effective reproduction number Re. We showed that for Re ≤ 1 there was a unique CFE and the disease would die out
wherever it started whereas for Re > 1 in addition to the CFE there was a unique CE and the disease would tend to the
CE if it was initially present. Simulations with realistic parameter values confirmed the results.
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